Advanced Non-Invasive Prenatal Testing for Paternal Inheritance and Fetal Genetic Analysis
The IVDNGS™ NIPT Panel is a cutting-edge non-invasive prenatal test based on Next-Generation Sequencing (NGS) that analyzes cell-free fetal DNA (cffDNA) from maternal blood to detect paternally inherited genetic variants. This panel provides early, safe, and accurate insight into the fetal genotype without posing any risk to the fetus.
Designed for pregnancies at risk of inherited disorders, this test enables detection of single-gene mutations, RhD status, and paternity, making it a valuable tool in personalized prenatal care.
Non-invasive analysis using maternal blood
Detects paternally inherited alleles, RhD gene, and mutations causing monogenic disorders
NGS-based approach for high precision and sensitivity
Ideal for early-stage pregnancies (as early as 10 weeks gestation)
Suitable for high-risk families or known paternal mutation carriers
Eliminates risks associated with invasive procedures like amniocentesis
Developed under strict ISO 13485 and IVD standards
| Parameter | Details |
|---|---|
| Test Name | IVDNGS™ NIPT (Non-Invasive Paternal Testing) Panel |
| Technology | Targeted Next-Generation Sequencing (NGS) |
| Sample Type | Maternal plasma (cell-free fetal DNA) |
| Analytes Detected | Paternally inherited alleles, RhD gene, Monogenic mutations |
| Gestational Age | From 10 weeks onwards |
| Clinical Applications | Paternity confirmation, RhD status, Monogenic disorder screening |
| Turnaround Time | 7–10 working days |
| Regulatory Compliance | ISO 13485, CE-IVD |
| Sensitivity/Specificity | ≥99% depending on target and fetal fraction |
Copyright © 2025 https://probgenbiotech.com/ All Rights Reserved.